RichardSLevyMD

PubMed

• 41 citations
  Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.
  Naresh Punwani, Timothy Burn, Peggy Scherle, Robert Flores, Jack G. Shi, Paul Collier, Denise Hertel, Patrick J. Haley, Yvonne Lo, Paul Waeltz, James D. Rodgers, Stace...> ;The British Journal of Dermatology. 2015 Oct 1
• 80 citations
  Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
  Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael W N Deininger, Carole B Miller, Richard T Silver, ...> ;Haematologica. 2015 Apr 1
• 33 citations
  Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
  Ruben A. Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard S. Levy, Andres Siulnik, Vikas Gupta, Mahmudul K...> ;Haematologica. 2014 Feb 1
• 329 citations
  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
  Francisco Cervantes, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andres Sirulnik, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, ...> ;Blood. 2013 Dec 12
• 52 citations
  Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
  Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael W N Deininger, Carole B Miller, Richard T Silver, ...> ;Haematologica. 2013 Dec 1
• 81 citations
  Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
  Moshe Talpaz, Ronald Paquette, Lawrence B. Afrin, Solomon I. Hamburg, Josef T. Prchal, Katarzyna Jamieson, Howard R. Terebelo, Gregory L. Ortega, Roger M. Lyons, Ramon...> ;Journal of Hematology & Oncology. 2013 Oct 29
• 28 citations
  Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
  Ruben A. Mesa, Alan L. Shields, Thomas Hare, Susan Erickson-Viitanen, William Sun, Nicholas J. Sarlis, Victor Sandor, Richard S. Levy, Srdan Verstovsek> ;Leukemia Research. 2013 Aug 1
• 63 citations
  Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
  Claire N. Harrison, Ruben A. Mesa, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Laurent Knoops, Margaret Squier, Andres Sirulnik, Estella Mendelson,...> ;British Journal of Haematology. 2013 Jul 1
• 75 citations
  The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
  Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver...> ;British Journal of Haematology. 2013 May 1
• 150 citations
  Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
  Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John Catalano, Michael W. Deininger, Alan L. Shields, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, J...> ;Journal of Clinical Oncology. 2013 Apr 1
• 1424 citations
  A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
  Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver...> ;The New England Journal of Medicine. 2012 Mar 1
• 131 citations
  Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
  Naresh Punwani, Peggy Scherle, Robert Flores, Jack G. Shi, Jinjin Liang, Swamy Yeleswaram, Richard S. Levy, William V. Williams, Alice B. Gottlieb> ;Journal of the American Academy of Dermatology. 2012 Oct 1
• 44 citations
  Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JA...
  Ruben A. Mesa, Hagop M. Kantarjian, Ayalew Tefferi, Amylou C. Dueck, Richard Levy, Kris Vaddi, Susan Erickson-Viitanen, Deborah A. Thomas, Jorge E. Cortes, Gautam Bort...> ;Cancer. 2011 Nov 1
• 893 citations
  Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
  Srdan Verstovsek, Hagop M. Kantarjian, Ruben A. Mesa, Animesh Pardanani, Jorge Cortes-Franco, Deborah A. Thomas, Zeev Estrov, Jordan S. Fridman, Edward C Bradley, Susa...> ;The New England Journal of Medicine. 2010 Sep 15
• 245 citations
  The 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients with Type 2 Diabetes Inadequately Controlled By Metformin Monoth...
  Julio Rosenstock, Salomon Banarer, Vivian Fonseca, Silvio E. Inzucchi, William Sun, Wenqing Yao, Gregory Hollis, Robert Flores, Richard S. Levy, William V. Williams, J...> ;Diabetes Care. 2010 Jul 1
• 23 citations
  An analysis of food and drug administration medical device reports relating to total joint components
  Frank P. Castro, George F. Chimento, Barry G. Munn, Richard S. Levy, Stephen Timon, Robert L. Barrack> ;The Journal of Arthroplasty. 1997 Oct 1
• 149 citations
  Cost of Treating an Infected Total Knee Replacement
  Christopher K. Hebert, Rodrek E. Williams, Richard S. Levy, Robert L. Barrack> ;Clinical Orthopaedics and Related Research. 1996 Oct 1
• 92 citations
  Drug and alcohol use in orthopedic trauma patients: a prospective study.
  Richard S. Levy, Christopher K. Hebert, Barry G. Munn, Robert L. Barrack> ;Journal of Orthopaedic Trauma. 1996 Jan 1
• Join now to see all